{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:49:21Z","timestamp":1776851361076,"version":"3.51.2"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Heparin-induced thrombocytopenia (HIT) is a life-threatening disorder caused by exposure to heparin and characterized by high morbidity and mortality. It is largely underestimated because of its heterogeneous presentation, ranging from a decrease in platelet count antibody positivity to serious thrombotic complications. Haemodialysis (HD) patients represent a high-risk population due to anticoagulation use during extracorporeal treatments. It usually occurs in the first weeks after the start of HD, although it has been reported in chronic HD patients after surgery procedures. When the diagnosis of HIT is formulated, heparin must be promptly stopped and an alternative anticoagulant has to be started. The aim of this review is to provide a comprehensive overview on the pathogenesis, diagnosis and treatment of HIT in HD in order to increase the awareness of physicians of this important clinical syndrome to promptly start the specific treatment.<\/jats:p>","DOI":"10.1093\/ckj\/sfag062","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:43:02Z","timestamp":1772023382000},"source":"Crossref","is-referenced-by-count":0,"title":["Heparin-induced thrombocytopenia: a challenging diagnosis in haemodialysis\u2014state of art and review of the literature"],"prefix":"10.1093","volume":"19","author":[{"given":"Ivana","family":"Capuano","sequence":"first","affiliation":[{"name":"Chair of Nephrology, University of Naples \u201cFederico II\u201d Department of Public Health, , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[{"name":"Chair of Nephrology, University of Naples \u201cFederico II\u201d Department of Public Health, , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-6209","authenticated-orcid":false,"given":"Pasquale","family":"Buonanno","sequence":"additional","affiliation":[{"name":"Reproductive and Odontostomatological Sciences, University of Naples \u201cFederico II\u201d Department of Neurosciences, , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Tufano","sequence":"additional","affiliation":[{"name":"Regional Reference Centre for Coagulation Disorders, University of Naples \u201cFederico II\u201d Department of Clinical Medicine and Surgery, , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Chair of Nephrology, University of Naples \u201cFederico II\u201d Department of Public Health, , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026042204514630400_bib1","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042204514630400_bib2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med"},{"key":"2026042204514630400_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026042204514630400_bib4","doi-asserted-by":"publisher","first-page":"10760296231177993","DOI":"10.1177\/10760296231177993","article-title":"Heparin-induced thrombocytopenia in chronic hemodialysis patients","volume":"29","author":"Hamadi","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026042204514630400_bib5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia: a comprehensive clinical review","volume":"67","author":"Salter","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026042204514630400_bib6","first-page":"3036476","article-title":"Pseudothrombocytopenia due to platelet clumping: a case report and brief review of the literature","volume":"2016","author":"Tan","year":"2016","journal-title":"Case Rep Hematol"},{"key":"2026042204514630400_bib7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3892\/ol.2012.675","article-title":"Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia associated with neuroendocrine carcinoma: a case report","volume":"4","author":"Kim","year":"2012","journal-title":"Oncol Lett"},{"key":"2026042204514630400_bib8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2176\/nmc.cr.2013-0263","article-title":"Chronic subdural hematoma in elderly patient with EDTA-dependent pseudothrombocytopenia recently treated with aspirin and warfarin: case report","volume":"54","author":"Tosa","year":"2014","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2026042204514630400_bib9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2169\/internalmedicine.55.5636","article-title":"Dialyzer-related thrombocytopenia due to a polysulfone membrane","volume":"55","author":"Kobari","year":"2016","journal-title":"Intern Med"},{"key":"2026042204514630400_bib10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2011.1499","article-title":"Use of electron-beam sterilized hemodialysis membranes and risk of thrombocytopenia","volume":"306","author":"Kiaii","year":"2011","journal-title":"JAMA"},{"key":"2026042204514630400_bib11","first-page":"143","article-title":"Relationship between platelet count and hemodialysis membranes","volume":"6","author":"Nasr","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026042204514630400_bib12","first-page":"291","article-title":"Diagnosis and management of heparin-induced thrombocytopenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2026042204514630400_bib13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","article-title":"Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia","volume":"10","author":"Perdomo","year":"2019","journal-title":"Nat Commun"},{"key":"2026042204514630400_bib14","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"2 Suppl","key":"2026042204514630400_bib15","doi-asserted-by":"publisher","first-page":"53S","DOI":"10.1378\/chest.11-2288","article-title":"Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"2026042204514630400_bib16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjh.19180","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: third edition","volume":"204","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"key":"2026042204514630400_bib17","article-title":"Heparin-induced thrombocytopenia","author":"Thrombosis Canada"},{"key":"2026042204514630400_bib18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5694\/mja2.51229","article-title":"Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia","volume":"215","author":"Chen","year":"2021","journal-title":"Med J Aust"},{"key":"2026042204514630400_bib19","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"2026042204514630400_bib20","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"2026042204514630400_bib21","doi-asserted-by":"crossref","DOI":"10.5772\/38876","article-title":"Management of heparin-induced thrombocytopenia in uremic patients with hemodialysis","volume-title":"Renal Failure \u2013 The Facts","author":"Matsuo"},{"key":"2026042204514630400_bib22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0272-6386(96)90134-1","article-title":"Heparin-induced thrombocytopenia in hemodialysis patients","volume":"28","author":"Yamamoto","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"2026042204514630400_bib23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000102052","article-title":"Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis","volume":"35","author":"Matsuo","year":"2006","journal-title":"Pathophysiol Haemos Thromb"},{"key":"2026042204514630400_bib24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.14740\/jh876","article-title":"Risk factors in hospitalized patients for heparin-induced thrombocytopenia by real world database: a new role for primary hypercoagulable states","volume":"10","author":"Kaur","year":"2021","journal-title":"J Hematol"},{"key":"2026042204514630400_bib25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1590\/2175-8239-jbn-2020-0109","article-title":"Dialysis-related thrombocytopenia: a case report","volume":"44","author":"Duayer","year":"2022","journal-title":"Braz J Nephrol"},{"key":"2026042204514630400_bib26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/1744-9987.12073","article-title":"Complications of native arteriovenous fistula: the role of color Doppler ultrasonography","volume":"18","author":"Visciano","year":"2014","journal-title":"Ther Apher Dial"},{"key":"2026042204514630400_bib27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/MOH.0b013e32830b84a2","article-title":"Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment","volume":"15","author":"Alberio","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"2026042204514630400_bib28","doi-asserted-by":"publisher","first-page":"e12573","DOI":"10.1002\/rth2.12573","article-title":"Heparin-induced thrombocytopenia in end-stage renal disease: reliability of the PF4-heparin ELISA","volume":"5","author":"Kelly","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2026042204514630400_bib29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.24006","article-title":"The platelet serotonin-release assay","volume":"90","author":"Warkentin","year":"2015","journal-title":"Am J Hematol"},{"key":"2026042204514630400_bib30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/molecules22040617","article-title":"Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review","volume":"22","author":"Minet","year":"2017","journal-title":"Molecules"},{"key":"2026042204514630400_bib31","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/jcm9041226","article-title":"Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia","volume":"9","author":"Tardy","year":"2020","journal-title":"J Clin Med"},{"key":"2026042204514630400_bib32","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1055\/a-1653-5065","article-title":"Heparin-induced thrombocytopenia diagnosis: a retrospective study comparing heparin-induced platelet activation test to 14C-serotonin release assay","volume":"5","author":"Gonthier","year":"2021","journal-title":"TH Open"},{"key":"2026042204514630400_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000450805","article-title":"A new polysulfone membrane dialyzer, NV, with low-fouling and antithrombotic properties","volume":"189","author":"Oshihara","year":"2017","journal-title":"Contrib Nephrol"},{"key":"2026042204514630400_bib34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5301\/ijao.5000608","article-title":"Prospective, randomized, multicenter, controlled trial (TRIATHRON 1) on a new antithrombogenic hydrophilic dialysis membrane","volume":"40","author":"Ronco","year":"2017","journal-title":"Int J Artif Organs"},{"key":"2026042204514630400_bib35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ramb.2012.11.004","article-title":"Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction","volume":"59","author":"Junqueira","year":"2013","journal-title":"Rev Assoc M\u00e9d Brasil"},{"key":"2026042204514630400_bib36","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.thromres.2009.10.008","article-title":"A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb Res"},{"key":"2026042204514630400_bib37","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1186\/cc6119","article-title":"Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study","volume":"11","author":"de\u00a0Pont","year":"2007","journal-title":"Crit Care"},{"key":"2026042204514630400_bib38","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2026042204514630400_bib39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/107602960100700409","article-title":"Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients","volume":"7","author":"Lindhoff-Last","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026042204514630400_bib40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"key":"2026042204514630400_bib41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1586\/ehm.10.53","article-title":"Pharmacology of argatroban","volume":"3","author":"Jeske","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"2026042204514630400_bib42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5694\/mja2.50213","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group","volume":"210","author":"Joseph","year":"2019","journal-title":"Med J Aust"},{"key":"2026042204514630400_bib43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11239-006-9019-2","article-title":"Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia","volume":"22","author":"Guzzi","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"2026042204514630400_bib44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1345\/aph.1E480","article-title":"Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia","volume":"39","author":"Tang","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2026042204514630400_bib45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1055\/s-0038-1648491","article-title":"Heparin-associated thrombocytopenia: the antibody is not heparin specific","volume":"67","author":"Greinacher","year":"1992","journal-title":"Thromb Haemost"},{"key":"2026042204514630400_bib46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1053-0770(97)90239-1","article-title":"Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis","volume":"11","author":"Schmahl","year":"1997","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026042204514630400_bib47","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1345\/aph.1Q177","article-title":"Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia","volume":"45","author":"Tsu","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2026042204514630400_bib48","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"2026042204514630400_bib49","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"2026042204514630400_bib50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"Bhatt","year":"2013","journal-title":"Eur J Haematol"},{"key":"2026042204514630400_bib51","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1345\/aph.1M136","article-title":"Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues","volume":"43","author":"Blackmer","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2026042204514630400_bib52","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/joneph\/20.3.370","article-title":"Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II","volume":"20","author":"Borawski","year":"2007","journal-title":"J Nephrol"},{"key":"2026042204514630400_bib53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1076029609338711","article-title":"Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide","volume":"15","author":"Adiguzel","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026042204514630400_bib54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/cc9993","article-title":"Heparin-induced thrombocytopenia in the ICU: an overview","volume":"15","author":"Sakr","year":"2011","journal-title":"Crit Care"},{"key":"2026042204514630400_bib55","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/ph17121584","article-title":"Danaparoid\u2014consensus recommendations on its clinical use","volume":"17","author":"Bauersachs","year":"2024","journal-title":"Pharmaceuticals"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag062\/67110961\/sfag062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/4\/sfag062\/67110961\/sfag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/4\/sfag062\/67110961\/sfag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:51:55Z","timestamp":1776847915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag062\/8497457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag062","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,25]]},"article-number":"sfag062"}}